Pfizer PFE · NYSE
$29.43 -0.51% (-$0.15)
Summary
42 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 15 years in a row.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 17 USD is left as free cash.
What to watch
- Revenue fell by 15% a year over the last 3 years.
- It pays out more in dividends than it earns: 226% of profit.
- Repaying its net debt would take 4.9 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.7 USD for 1 USD of yearly profit. Over the last five years it was 27.7 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 8.5% a year over 5 years. Over the last 3 years it fell by 15% a year. For the next fiscal year analysts expect revenue to fall by 0.5%. Earnings per share fell by 37% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 29 USD
- Research and development 20 USD
- Sales and administration 26 USD
- Taxes and other 18 USD
- Net profit 6.8 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 6.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 5.84%
- Paid out of profit
- 226%
- Raised in a row
- 15 years
You receive $1.72 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 16
- Hold 23
- Sell 1
Today's price within the analysts' price targets
The average target of $28.5 is 3.2% below today's price. 40% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Biopharma Segment 98%
- Segment Reporting, Reconciling Item, Corporate Nonsegment 2.2%
By region
- UNITED STATES 59%
- Developed Rest Of World 26%
- Emerging Markets 15%
Biopharma Segment brings in 98% of revenue.
Segments in detail